Atacicept

Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease[1][2].

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

Atacicept (TACI-Ig; 100 μg; i.p.; three times of week for 14 days; BALB/c mice) reduces mature B-cell counts and serum antibody levels in normal mice[1]. Atacicept (TACI-Ig) inhibits the progression of disease and autoantibody titers in a mouse model of collagen-induced arthritis (CIA)[1]. Animal Model: Male DBA/1 mice with CIA models[1] Dosage: 100 μg Administration: intraperitoneal injection; three times of week for 21 days Result: Increased serum titers of anti-collagen Abs and few overt signs of disease. Animal Model: BALB/c mice[1] Dosage: 100 μg Administration: intraperitoneal injection; three times of week for 14 days Result: Reduced mature B cell populations but had little effect on other cell lineages. Blocked the development of B cells at the transition from T1 to T2 and the development of MZ B cells in the spleen. Decerased the serum levels of IgM about 2.3-fold.

[1]. Gross JA, et, al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001 Aug;15(2):289-302.   

[2]. Gross JA, et, al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000 Apr 27;404(6781):995-9.